The importance of Phase I/II trials in pediatric oncology

Investigational New Drugs

Volumn 14, Issue 1, 1996, Pages 33-35

  MacArthur, Craig A ^a   Vietti, Teresa ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chemotherapy; Clinical trials; Pediatrics; Phase I II

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER SURVIVAL; CANCER THERAPY; CHILDHOOD CANCER; CLINICAL TRIAL; HUMAN; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0029790250     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00173680     Document Type: Review

References (11)

1. Robison LL: General principles of the epidemiology of childhood cancer. In: Pizzo PA, Poplack DG (eds.) Principles and Practice of Pediatric Oncology. 2nd ed, J.B. Lippincott, Philadelphia, p 8, 1993
2. Hurwitz CA, Relling MV, Weitman SD, Ravindranath V, Vietti TJ, Strother DR, Ragab AH, Pratt CB: Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 11:2324-2329, 1993
3. Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, Horowitz ME, Reaman G, Hammond GD: Phase I and pharmacologic evaluation of all-trans retinoic acid in pediatric patients. J Clin Oncol 10:1666-1673, 1992
4. Balis FM, Holcenberg JS, Poplack DG: General principles of chemotherapy. In: Pizzo PA, Poplack DG (eds.) Principals and Practice of Pediatric Oncology. 2nd ed, J.B. Lippincott, Philadelphia, pp 231-232, 1993
5. Venditti JM: Preclinical drug development: rationale and methods. Semin Oncol 8:349-361, 1981
6. Marsoni S, Ungerleider RS, Hurson SB, Simon RM, Hammershaimb LD: Tolerance to antineoplastic agents in children and adults. Cancer Treat Rep 69:1263-1269, 1985
7. Carlson L, Ho P, Smith M, Reisch J, Weitman S: Pediatric Phase I drug tolerance: a review and comparison of recent adult and pediatric Phase I trials. Am J Fed Hem One: in press, 1996
8. Pieters R, Kongo T, Loonen AH, Huismans DR, Broxterman HJ, Hahlen K, Veerman AJ: Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukemia. Br J Cancer 65:691-697, 1992
9. Hecker S, Sauerbrey A, Volm M: p53 expression and poor prognosis in childhood acute lymphoblastic leukemia. Anticancer Res 14:2759-2761, 1994
10. Horowitz ME, Etcubanas E, Christensen ML, Houghton JA, George SL, Green AA, Houghton PJ: Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 6:308-314, 1988
11. Castleberry RP, Cantor AB, Green AA, Joshi V, Berkow RL, Buchanan GR, Leventhal B, Mahoney DH, Smith EI, Hayes FA: Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 12:1616-1620, 1994